Eisai Inc.
Global Headquarters:
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 Japan
US Headquarters: 100 Tice Blvd.
Woodcliff Lake
New Jersey
07677
United States
522 articles about Eisai Inc.
-
C₂N Diagnostics, LLC Announces Investment From Eisai Inc.
3/6/2024
C₂N Diagnostics, LLC, a leader in advanced brain health diagnostics, and Eisai Inc., a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
-
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
3/5/2024
Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N's efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer's disease in the U.S.
-
EISAI TO PRESENT DATA ON LECANEMAB and OTHER ALZHEIMER'S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING
2/28/2024
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™) from March 5-9 in Lisbon, Portugal, and virtually.
-
Thanks to a rough launch of its Biogen-partnered Alzheimer’s disease treatment, Eisai will likely miss its target of treating 10,000 patients with Leqembi by the end of March 2024.
-
The European Medicines Agency's Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArctic
1/11/2024
BioArctic AB's partner Eisai announced that the Scientific Advisory Group will convene to discuss the Marketing Authorisation Application of lecanemab, which is currently under review by the European Medicines Agency.
-
Angle PLC - Contract announcement with Eisai Inc.
1/2/2024
ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce that it has signed a contract with the global pharmaceutical company, Eisai Inc..
-
Recent FDA approvals of novel drugs based on less-than-stellar clinical evidence point to a trend toward regulatory flexibility—particularly in indications with very high unmet need.
-
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR
12/21/2023
Merck and Eisai announce that KEYTRUDA® plus LENVIMA® is now reimbursed with clinical criteria and conditions under the British Columbia, Alberta, Saskatchewan, Ontario, Quebec, Nova Scotia, New Brunswick, and Newfoundland drug plans, for adult patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient, who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.
-
LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20
12/13/2023
BioArctic AB's partner Eisai announced that LEQEMBI will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance drug price list.
-
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
12/8/2023
At the final analysis, KEYTRUDA plus LENVIMA did not improve OS or PFS sufficiently to meet the study’s prespecified statistical criteria in the first-line treatment of certain patients with advanced or recurrent endometrial carcinoma versus a standard of care, platinum-based chemotherapy doublet (carboplatin plus paclitaxel).
-
After winning traditional approval from the U.S. regulator, Eisai’s Alzheimer’s disease therapy Leqembi has seen a sharp increase in patient uptake, with a target of 10,000 patients by March 2024.
-
Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today
11/7/2023
BioArctic AB's partner Eisai held a presentation on the second quarter of Eisai's fiscal year, ending March 2024.
-
Subcutaneous injections of Eisai and Biogen’s Leqembi led to numerically greater amyloid removal than the intravenous version of the Alzheimer’s disease therapy, though risks of brain swelling and bleeding remained.
-
KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
10/25/2023
Merck and Eisai announced today that KEYTRUDA®, an anti-PD-1 therapy, in combination with LENVIMA with respective clinical criteria and conditions for adult patients with advanced (not amenable to curative surgery or radiation) or metastatic renal cell carcinoma (RCC), with no prior systemic therapy for metastatic RCC.
-
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results & Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The CTAD Conference
10/25/2023
Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new data for LEQEMBI® 100 mg/mL injection for intravenous use, in the Late Breaking Symposium 4 "Lecanemab for Early Alzheimer’s Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration" at the 16th annual Clinical Trials on Alzheimer’s Disease conference held in Boston, Massachusetts, United States and virtually October 24-27, 2023.
-
LEQEMBI® (lecanemab-irmb) Named One of Time's Best Inventions of 2023
10/24/2023
Eisai Inc. and Biogen Inc. are honored to announce that TIME has selected LEQEMBI® as one of the Best Inventions of 2023 in the Medical Care category.
-
Lecanemab named one of the world's best inventions in 2023 by TIME
10/24/2023
BioArctic AB and partner Eisai are proud to announce that TIME has selected lecanemab as one of the Best Inventions of 2023 in the medical care category.
-
New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD
10/16/2023
BioArctic AB's partner Eisai will present new data from the phase 3 Clarity AD study for its Alzheimer's disease treatment LEQEMBI® 100 mg/mL injection for intravenous use, as well as new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer's Disease conference.
-
Eisai to Present New Data From LEQEMBI® (lecanemab-irmb) Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
10/16/2023
Eisai Co. Ltd announced that the company will present new data from the phase 3 Clarity AD study for its Alzheimer's disease treatment LEQEMBI® 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer's Disease conference.
-
Eisai to Present Research From Oncology Portfolio and Pipeline at ESMO Congress 2023
10/11/2023
Eisai announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2023, which is taking place virtually and in-person in Madrid, Spain from October 20 to 24.